Distribution of medicines and pharmaceutical materials is adopting FMCG principles. However, regulated goods place higher demands on data

Fast-moving consumer goods retail bases availability management on the continuous integration of data on orders, deliveries, inventory, and sales. Pharmaceutical distribution is moving toward this way of handling operational data, but it must supplement it with requirements for the control and traceability of regulated products. At PHOENIX, unifying data flows reduced the volume of manual checks by up to 95%, and the process from receipt to stocking was shortened from days to hours. Thus, drug availability is determined not only by the physical state of the inventory but also by the company's ability to verify the necessary data in a timely manner and reflect it in subsequent operations.

Pharmaceutical companies are facing dual pressure. Regulatory requirements remain high, while pharmacies, hospitals, and other customers expect availability, speed, and predictability comparable to advanced retail. For manufacturers and distributors, the deciding factor will not only be the ability to meet obligations associated with regulated products, but also whether they can be operationally reliable and preferred partners for their customers. In an environment where an unavailable drug can be ordered from another distributor, the quality of operational data becomes a component of a company's business relevance.

The largest distribution centers of PHOENIX handle approximately 35,000 items. When ordering, a pharmacy does not evaluate whether the drug is physically sitting in the distributor's warehouse. It decides based on whether it is listed as available at that moment. If it is not, they look for it at another supplier.

It is precisely in availability management that pharmaceutical distribution is moving closer to retail. The growing number of items, transactions, and distribution channels requires continuous connectivity of information regarding orders, pending deliveries, receipts, and inventory. The company must know in advance what is arriving, in what quantity, and under what conditions. Without this data, receiving can only be managed once the shipment is at the loading dock.

Physical stock and available stock are not the same

In pharmaceutical distribution, goods cannot be made available to customers simply based on confirmation that they have arrived at the warehouse. Before release, it is necessary to verify identity, quantity, batch, expiration, documentation, and, depending on the nature of the product, transport or temperature conditions.

These requirements correspond to the WHO Good Distribution Practices, according to which medicinal products are exposed to risks during purchase, storage, transport, repackaging and distribution itself. The management of these risks therefore requires documented processes and available records across the individual parts of the supply chain. The requirements for storage, transport and traceability are further specified in the SÚKL guidelines for the distribution of medicinal products. The control therefore concerns not only the physical condition of the goods, but also the completeness of the records that document the conditions of their movement through the distribution chain.

A single piece of data therefore serves several functions here. The batch affects inventory records, traceability, and the ability to react during a drug recall. Expiration enters into inventory turnover management and decisions on whether a product can still be distributed. Information about transport conditions proves whether the required standards were maintained.

Data requirements are therefore broader than in standard retail operations. Accuracy and processing speed must be accompanied by completeness, evidentiary value, and the ability to retrospectively document individual steps of the distribution process.

For company management, a relevant indicator is therefore the time from receipt to availabilityIt shows how long it takes for physically received goods to become stock that can actually be offered to a customer. At the same time, it reveals what portion of the process consists of necessary inspections and how much is consumed by manual document matching, data retrieval, and resolving discrepancies.

The example of PHOENIX shows that higher regulatory requirements do not automatically mean slower operations. If data is available before a shipment arrives, is interconnected, and allows for system-based checks, staff can focus on cases that truly require expert assessment. The results of one distributor cannot be generalized to the entire market. However, it demonstrates that data quality affects the availability of medicines just as significantly as warehouse and transport capacity.

The pharmaceutical industry is not adopting the retail model in its entirety. It is moving closer to it by requiring fast and accurate management of high volumes of items and transactions. At the same time, it must maintain a level of control appropriate to the regulated nature of the goods.

Availability as a component of partner reliability

GRiT helps pharmaceutical manufacturers, distributors, and wholesalers connect the flow of goods, data, and documents so that information about orders, deliveries, and stock is available in time for downstream management. Connected data makes it possible to reduce manual matching, convert received goods into available stock faster, and simultaneously maintain the necessary control and traceability.

Find out how data and processes can be connected in pharmaceutical distribution to support availability, traceability, and reliability for business partners.